---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-018595"
form_type: "8-K"
ticker: "MIRA"
cik: "0001904286"
company_name: "MIRA PHARMACEUTICALS, INC."
filed_at: "2025-07-10T23:59:59+00:00"
generated_at: "2026-05-18T08:47:38.426712+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# MIRA reports SKNY-1 reverses anxiety behavior in animal model, differentiating from older CB1 drugs

## Summary
- SKNY-1 reversed anxiety-like behavior in zebrafish induced by a CB1 activator, normalizing to control or better levels.
- Prior results showed SKNY-1 achieved up to 30% weight loss, reversed nicotine craving, and preserved muscle mass in animal models.
- SKNY-1 is designed to avoid CNS side effects that halted earlier CB1 drugs like rimonabant.
- Company is preparing for shareholder approval for acquisition of SKNY Pharmaceuticals; expects to start IND-enabling studies.

## SEC filing metadata
- accession: 0001641172-25-018595
- form_type: 8-K
- ticker: MIRA
- cik: 0001904286
- company_name: MIRA PHARMACEUTICALS, INC.
- filed_at: 2025-07-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1904286/000164117225018595/0001641172-25-018595-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1904286/000164117225018595/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-018595
- JSON: https://secwatch.observer/filing/0001641172-25-018595.json
- Plain text: https://secwatch.observer/filing/0001641172-25-018595.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.